Rezolute, Inc. filed a free writing prospectus on November 13, 2026, announcing the pricing of an underwritten public offering of common stock and pre-funded warrants expected to raise approximately $100 million in gross proceeds.

Key Highlights

  • Offering size: 22,040,976 shares of common stock priced at $3.87 per share, plus pre-funded warrants for up to 3,800,000 shares at $3.869 per warrant.
  • Gross proceeds: Approximately $100 million, before deducting underwriting discounts, commissions, and other offering expenses, according to the filing.
  • Lead investor: The financing is being led by Frazier Life Sciences, with participation from new and existing funds.
  • Expected closing: On or about November 16, 2026, subject to the satisfaction of customary closing conditions.
  • Intended use of proceeds: The company disclosed plans to use net proceeds, together with existing cash and cash equivalents, to fund ersodetug commercialization preparation, working capital, and general corporate purposes.
  • Registration basis: Securities are being offered under a Form S-3 shelf registration statement (File No. 333-299867), filed November 5, 2026, and declared effective November 10, 2026.

Rezolute's $100 Million Capital Raise: Pricing Terms and Structure

According to the free writing prospectus filed November 13, 2026, Rezolute, Inc. (NASDAQ:RZLT) priced an underwritten offering consisting of two securities: 22,040,976 shares of common stock at $3.87 per share, and pre-funded warrants exercisable for up to 3,800,000 shares at $3.869 per warrant. The filing noted that the pre-funded warrant price represents the per share offering price for the common stock, less the $0.001 per share exercise price for each such pre-funded warrant. The gross proceeds are expected to be approximately $100 million before deducting underwriting discounts, commissions, and other offering expenses.

The filing identified Morgan Stanley, Guggenheim Securities, and Cantor as joint book-running managers for the offering. H.C. Wainwright and Co. and Jones are acting as lead managers, while Maxim Group LLC and Lake Street Capital Markets, LLC are acting as co-managers. The offering is being conducted under a shelf registration statement on Form S-3 that was declared effective by the SEC on November 10, 2026.

The company disclosed that it intends to use the net proceeds, together with its existing cash and cash equivalents, to fund ersodetug commercialization preparation, working capital, and general corporate purposes. Rezolute described itself as "a late-stage ultra-rare, metabolic disease company focused on treating refractory hypoglycemia caused by any form of hyperinsulinism (HI)." The filing noted that statements regarding anticipated use of proceeds and completion of the offering are forward-looking statements subject to the company's cautionary language.

What Was Disclosed

Rezolute filed a free writing prospectus dated November 13, 2026, disclosing the pricing of an approximately $100 million underwritten offering of common stock and pre-funded warrants, led by Frazier Life Sciences, with an expected closing on or about November 16, 2026.